Colgate-Palmolive Q2 2026: EPS Beat, Restructuring Expansion, and $5B Buyback Program
CL sits 21% above its 52-week low of $74.545.
Summary
Colgate-Palmolive beat Q2 earnings estimates and raised its full-year outlook, but also expanded its restructuring program, now expected to cost up to $550 million. The company continues to return cash to shareholders via buybacks.
Key Events · Earnings and Guidance · CL
-
Q2 Earnings Beat
Adjusted EPS of $0.99 exceeded the $0.95 consensus. Organic sales grew 2.4%, with net sales up 4.9% to $5,361 million, driven by Oral Care and Latin America.
-
Full-Year Guidance Raised
Management raised its 2026 Base Business EPS growth outlook to mid-single-digit from low- to mid-single-digit, reflecting confidence in underlying momentum.
-
Restructuring Program Expanded
The Strategic Growth and Productivity Program was expanded in April 2026, with cumulative pre-tax charges now estimated at $350–$550 million. Q2 charges were $129 million pre-tax, primarily in Other (income) expense.
-
Share Repurchases Continue
The company repurchased 3.2 million shares for $284 million in Q2 under its $5 billion buyback program, with $3.53 billion remaining authorization.
Analysis · CL · Industrial Applications And Services
A solid quarter saw adjusted EPS of $0.99, beating consensus by $0.04, and prompting a full-year earnings outlook raise to mid-single-digit growth. Organic sales rose 2.4%, led by Oral Care and Latin America. Yet GAAP operating profit fell 6%, weighed down by $129 million in restructuring charges tied to the expanded Strategic Growth and Productivity Program—now projected to cost $350–$550 million cumulatively. Share repurchases totaled $284 million in the quarter under the $5 billion buyback program. While the earnings beat and guidance lift are encouraging, the restructuring expansion underscores ongoing cost pressures and portfolio realignment. Talcum powder litigation continues to mount, with 525 cases pending, though settlements remain immaterial. Overall, the quarter reflects resilience in core categories but also the price of transformation.
At the time of this filing, CL was trading at $89.95 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $73.3B. The 52-week trading range was $74.55 to $99.33. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.